Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: glass 0.5 full who wrote (4220)	4/27/2016 3:06:02 PM
From: Biomaven	Read Replies (1) \| Respond to of 4474

Look at the weight of the mouse at the higher dose needed to cause actual regression in the HER2 model. That's not a happy rodent. Peter

To: glass 0.5 full who wrote (4220)	4/27/2016 9:39:48 PM
From: jaybe	1 Recommendation Recommended By tktom Read Replies (1) \| Respond to of 4474

I think EGFR is used as a comparator since inhibiting EGFR WT is a known limiting toxicity. I'm not counting Her2 out yet but there is room for doubt, or discount, for valuing this cohort. However, this is nothing like Ariad's claim for briga in T790M EGFR. '788's pre-clinical shows cellular IC50's for Her2 Ex. 20 at ~6-26nM, which is at least ~10 times more potent than '113's cellular IC50's for EGFR mutants at 112-694nM (Briga inhibits cellular ALK WT at 17nM for comparison) [Ref. ASCO poster 2013]. So there is likely therapeutic window in Her2, but the higher dose and toxicity could make '788 vulnerable to a better Her2 inhibitor in the future.